DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine.
- Publisher:
- Wiley
- Publication Type:
- Journal Article
- Citation:
- International Journal of Cancer, 2022, 151, (12), pp. 2068-2081
- Issue Date:
- 2022-12-15
Open Access
Copyright Clearance Process
- Recently Added
- In Progress
- Open Access
This item is open access.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Fatemi, N | |
dc.contributor.author | Tierling, S | |
dc.contributor.author | Es, HA | |
dc.contributor.author | Varkiani, M | |
dc.contributor.author | Mojarad, EN | |
dc.contributor.author | Aghdaei, HA | |
dc.contributor.author | Walter, J | |
dc.contributor.author | Totonchi, M | |
dc.date.accessioned | 2023-06-30T20:41:09Z | |
dc.date.available | 2022-06-08 | |
dc.date.available | 2023-06-30T20:41:09Z | |
dc.date.issued | 2022-12-15 | |
dc.identifier.citation | International Journal of Cancer, 2022, 151, (12), pp. 2068-2081 | |
dc.identifier.issn | 0020-7136 | |
dc.identifier.issn | 1097-0215 | |
dc.identifier.uri | http://hdl.handle.net/10453/171046 | |
dc.description.abstract | Colorectal cancer (CRC) is the second leading cause of cancer death worldwide that is attributed to gradual long-term accumulation of both genetic and epigenetic changes. To reduce the mortality rate of CRC and to improve treatment efficacy, it will be important to develop accurate noninvasive diagnostic tests for screening, acute and personalized diagnosis. Epigenetic changes such as DNA methylation play an important role in the development and progression of CRC. Over the last decade, a panel of DNA methylation markers has been reported showing a high accuracy and reproducibility in various semi-invasive or noninvasive biosamples. Research to obtain comprehensive panels of markers allowing a highly sensitive and differentiating diagnosis of CRC is ongoing. Moreover, the epigenetic alterations for cancer therapy, as a precision medicine strategy will increase their therapeutic potential over time. Here, we discuss the current state of DNA methylation-based biomarkers and their impact on CRC diagnosis. We emphasize the need to further identify and stratify methylation-biomarkers and to develop robust and effective detection methods that are applicable for a routine clinical setting of CRC diagnostics particularly at the early stage of the disease. | |
dc.format | Print-Electronic | |
dc.language | eng | |
dc.publisher | Wiley | |
dc.relation.ispartof | International Journal of Cancer | |
dc.relation.isbasedon | 10.1002/ijc.34186 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | 1112 Oncology and Carcinogenesis | |
dc.subject.classification | Oncology & Carcinogenesis | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | DNA Methylation | |
dc.subject.mesh | Epigenesis, Genetic | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Precision Medicine | |
dc.subject.mesh | Reproducibility of Results | |
dc.subject.mesh | Humans | |
dc.subject.mesh | DNA Methylation | |
dc.subject.mesh | Precision Medicine | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | Reproducibility of Results | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | Epigenesis, Genetic | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | Reproducibility of Results | |
dc.subject.mesh | DNA Methylation | |
dc.subject.mesh | Epigenesis, Genetic | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | Precision Medicine | |
dc.subject.mesh | Humans | |
dc.subject.mesh | DNA Methylation | |
dc.subject.mesh | Precision Medicine | |
dc.subject.mesh | Colorectal Neoplasms | |
dc.subject.mesh | Reproducibility of Results | |
dc.subject.mesh | Biomarkers, Tumor | |
dc.subject.mesh | Epigenesis, Genetic | |
dc.title | DNA methylation biomarkers in colorectal cancer: Clinical applications for precision medicine. | |
dc.type | Journal Article | |
utslib.citation.volume | 151 | |
utslib.location.activity | United States | |
utslib.for | 1112 Oncology and Carcinogenesis | |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Engineering and Information Technology/School of Biomedical Engineering | |
utslib.copyright.status | open_access | * |
pubs.consider-herdc | false | |
dc.date.updated | 2023-06-30T20:41:07Z | |
pubs.issue | 12 | |
pubs.publication-status | Published | |
pubs.volume | 151 | |
utslib.citation.issue | 12 |
Abstract:
Colorectal cancer (CRC) is the second leading cause of cancer death worldwide that is attributed to gradual long-term accumulation of both genetic and epigenetic changes. To reduce the mortality rate of CRC and to improve treatment efficacy, it will be important to develop accurate noninvasive diagnostic tests for screening, acute and personalized diagnosis. Epigenetic changes such as DNA methylation play an important role in the development and progression of CRC. Over the last decade, a panel of DNA methylation markers has been reported showing a high accuracy and reproducibility in various semi-invasive or noninvasive biosamples. Research to obtain comprehensive panels of markers allowing a highly sensitive and differentiating diagnosis of CRC is ongoing. Moreover, the epigenetic alterations for cancer therapy, as a precision medicine strategy will increase their therapeutic potential over time. Here, we discuss the current state of DNA methylation-based biomarkers and their impact on CRC diagnosis. We emphasize the need to further identify and stratify methylation-biomarkers and to develop robust and effective detection methods that are applicable for a routine clinical setting of CRC diagnostics particularly at the early stage of the disease.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph